6887 (6887) Fair Value & Analysis

Healthcare · Market cap HK$21.7B

6 6887 6887 · HK

PriceHK$37.68

Fair ValueHK$10.93

Upside-71.0%

Quality51/100

Watch 6887 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$8.12 – HK$13.66

Fair value as of: Jul 2, 2026

From 25 valuation models · updated today

Share price +3.2% over the past month.

Price vs Fair Value (11 months)

11‑month range HK$32.44 – HK$59.90 · fair‑value band HK$8.12 – HK$13.66 · the HK$37.68 price screens above the HK$10.93 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6887 (6887) currently trades at HK$37.68, while our model-based Fair Value estimate is HK$10.93 — implying the stock looks roughly 71.0% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 6887 generated revenue of HK$4.8B at a net margin of 5.7%. Revenue grew 100.2% year over year. It earns a return on equity of 6.1%. Net debt stands at HK$2.6B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$4.8B

Revenue growth (YoY) +100%

Net margin 5.7%

Return on equity 6.1%

Free cash flow HK$228M FY2025

P/E ratio 58.9

More key figures

Operating margin 17.6%

Net debt HK$2.6B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

6887 reported revenue of HK$4.8B in FY2025 versus HK$3.8B in FY2022, a compound +8.1%/yr. Reported net income was HK$272M in FY2025.

Revenue +8.1%/yr

FY22 HK$3.8B

FY23 HK$6.4B

FY24 HK$4.0B

FY25 HK$4.8B

Net income

FY22 −HK$1.2B

FY23 HK$185M

FY24 −HK$207M

FY25 HK$272M

Is 6887 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,786	₹991.46	-44%
Zoetis Inc Z1TS34	R$25.93	R$19.70	-24%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6887 (6887) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$10.93 versus a price of HK$37.68 — about −71% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6887?

Our model-based fair value for 6887 is HK$10.93 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$37.68.

What is the quality score of 6887?

6887 has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6887 (6887)?

6887 reported trailing-twelve-month revenue of about HK$4.8B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6887?

The net profit margin of 6887 is about 5.7%, meaning it keeps roughly 5.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.